Murtaza Khorakiwala, managing director of Wockhardt, discusses the company’s vast international expertise in the manufacturing of pharmaceuticals and biopharmaceutical formulations in their 12 US FDA, UK MHRA and EMA compliant manufacturing facilities in India, as well as the out-licensing of its products into other regions to capture and penetrate new markets.
The Indian market still accounts for about 30-35 percent of the global business, the European market is another 35 percent, US is approximately 20 percent and emerging markets is about 10 percent
